Alkermes plc - Ordinary Shares (NQ:ALKS)

31.85 -1.54 (-4.61%)

Streaming Delayed Price Updated: 2:04 PM EST, Feb 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Alkermes (ALKS) Q4 2025 Earnings Call Transcript ↗

Today 9:55 EST

Alkermes (ALKS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction ↗

Today 8:20 EST

Via Chartmill

Topics Earnings

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

Today 7:00 EST

From Alkermes plc

Via Business Wire

Alkermes plc Announces CEO Succession Plan

Today 6:55 EST

From Alkermes plc

Via Business Wire

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗

November 19, 2025

Via Stocktwits

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Preview: Alkermes's Earnings ↗

October 27, 2025

Via Benzinga

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Alkermes plc

Via Business Wire

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Topics Regulatory Compliance

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

February 12, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

February 11, 2026

From Alkermes plc

Via Business Wire

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

January 06, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 30, 2025

From Alkermes plc

Via Business Wire

Alkermes to Participate in Two Upcoming Investor Conferences

November 25, 2025

From Alkermes plc

Via Business Wire

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗

November 14, 2025

Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.

Via Benzinga

Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid ↗

November 14, 2025

A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center.

Via Investor's Business Daily

Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes ↗

November 14, 2025

Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study ↗

November 12, 2025

Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulness and sleepiness scores.

Via Benzinga

This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗

November 11, 2025

Via Benzinga

ALKERMES PLC (NASDAQ:ALKS) Q3 2025 Earnings Beat Estimates and Drive Stock Surge ↗

October 28, 2025

Alkermes (ALKS) Q3 2025 earnings crush estimates with a 58% EPS beat and $394.2M revenue. The company raises its full-year 2025 financial guidance.

Via Chartmill

Topics Earnings

Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups ↗

October 24, 2025

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors.

Via Benzinga

Topics Government

Breaking Down Alkermes: 8 Analysts Share Their Views ↗

October 23, 2025

Via Benzinga

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz ↗

October 22, 2025

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.

Via Benzinga

Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition

October 22, 2025

DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for...

Via MarketMinute

Topics Intellectual Property

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avadel Pharmaceuticals plc (Nasdaq – AVDL), Middlefield Banc Corp. (Nasdaq – MBCN), Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated

October 22, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.